Genetic Technologies (Genetic Technologies) EV-to-Revenue : (As of Apr. 25, 2024)

View and export this data going back to 2002. Start your Free Trial

What is Genetic Technologies EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Genetic Technologies's enterprise value is $7.17 Mil. Genetic Technologies's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Genetic Technologies's EV-to-Revenue for today is .

The historical rank and industry rank for Genetic Technologies's EV-to-Revenue or its related term are showing as below:

GENE' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.32 Med: 10.51 Max: 1285.18
Current: 1.23

During the past 13 years, the highest EV-to-Revenue of Genetic Technologies was 1285.18. The lowest was 0.32. And the median was 10.51.

GENE's EV-to-Revenue is ranked better than
76.11% of 226 companies
in the Medical Diagnostics & Research industry
Industry Median: 3.11 vs GENE: 1.23

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-25), Genetic Technologies's stock price is $2.20. Genetic Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Therefore, Genetic Technologies's PS Ratio for today is .

Genetic Technologies EV-to-Revenue Historical Data

The historical data trend for Genetic Technologies's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Technologies EV-to-Revenue Chart

Genetic Technologies Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EV-to-Revenue

Get a 7-Day Free Trial

619.87

2,383.69

462.35

2.45

2.48

Genetic Technologies Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															-	-	2.48	-	-

Competitive Comparison of Genetic Technologies's EV-to-Revenue

For the Diagnostics & Research subindustry, Genetic Technologies's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genetic Technologies's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Genetic Technologies's EV-to-Revenue falls into.

Genetic Technologies EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Genetic Technologies's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	7.169	/	0
	=

Genetic Technologies's current Enterprise Value is $7.17 Mil.
Genetic Technologies's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Genetic Technologies (NAS:GENE) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Genetic Technologies's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	2.20	/	0
	=

Genetic Technologies's share price for today is $2.20.
Genetic Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

Genetic Technologies EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetic Technologies (Genetic Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (NAS:GENE) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

DU8:Germany GTG:Australia

Address

60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065

Website

https://www.gtglabs.com

Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.